Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,575 stopped studies mapped to Malignant Breast Neoplasm and descendants · 90% state a reason
Over the 1,575 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05032079 | Subzero and Scorpion Trial | N/A | withdrawn | Sep 2, 2021 | Larkin Community Hospital | Study Period Ended / Not Completed | Other (stated, no rule matched) |
| NCT05414123 | A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using…(FORESEE) | — | terminated | Jun 10, 2022 | Biocept, Inc. | The sponsor can no longer financially support the trial. | Funding |
| NCT04562233 | Breast Cancer and Resistance Exercise Program(B-REP) | N/A | terminated | Sep 24, 2020 | Rutgers, The State University of New Jersey | PI left | Investigator |
| NCT04625517 | Performance of Contrast-Enhanced Spectral Mammography to Assess Neoadjuvant Chemotherapy… | Phase 4 | terminated | Nov 12, 2020 | University of Texas Southwestern Medical Center | Low enrollment | Enrollment / accrual |
| NCT03190967 | T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of… | Phase 1 / Phase 2 | terminated | Jun 19, 2017 | National Cancer Institute (NCI) | The phase II portion was never started as we could no longer get the drug from the manufacturer. | Drug supply |
| NCT04265274 | Vinorelbine, Cisplatin, Disulfiram and Copper in CTC_EMT Positive Refractory Metastatic… | Phase 2 | withdrawn | Feb 11, 2020 | National Cancer Institute, Slovakia | Poor acrual | Other (stated, no rule matched) |
| NCT01873833 | Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating… | Phase 2 | terminated | Jun 10, 2013 | University of Southern California | Insufficient accrual | Enrollment / accrual |
| NCT03916068 | Acute Post-Radiation Hyperbaric Oxygen (HBO2) for Breast Cancer Patients Who Have… | Phase 2 | terminated | Apr 16, 2019 | Legacy Health System | Insufficient enrollment | Enrollment / accrual |
| NCT04139993 | RBX7455 Before Surgery for the Treatment of Operable Breast Cancer | Phase 1 | terminated | Oct 25, 2019 | Mayo Clinic | poor accrual | Enrollment / accrual |
| NCT03803761 | A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer | Phase 1 / Phase 2 | withdrawn | Jan 15, 2019 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT05371860 | Radiation Omission in Patients With HER2 Overexpressing Tumors With Pathologic Complete… | Phase 2 | withdrawn | May 12, 2022 | Armando Giuliano | PI voluntarily closed the study. Will be reopened as a national cooperative group trial. | Other (stated, no rule matched) |
| NCT01276704 | Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer | Phase 2 | terminated | Jan 13, 2011 | Carol Fabian, MD | accrual rate lower than anticipated; funding expired | Enrollment / accrual |
| NCT04106167 | Long-term, Non-interventional, Observational Study Following Treatment With Fate… | — | terminated | Sep 26, 2019 | Fate Therapeutics | This study was terminated by the Sponsor. | Other (stated, no rule matched) |
| NCT05395052 | FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors | Phase 1 | terminated | May 27, 2022 | Fate Therapeutics | This study was terminated by the Sponsor. | Other (stated, no rule matched) |
| NCT00934895 | Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic… | Phase 1 / Phase 2 | terminated | Jul 8, 2009 | Rutgers, The State University of New Jersey | Closed early due to slow accrual | Enrollment / accrual |
| NCT04170335 | Effects of Bariatric Surgery on Breast Density Improvement and Impact on Breast Cancer… | — | withdrawn | Nov 20, 2019 | The Cleveland Clinic | No inclusion | Other (stated, no rule matched) |
| NCT00665457 | Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast… | Phase 2 | terminated | Apr 23, 2008 | University of Nebraska | study drug was removed from the market and low enrollment. | Enrollment / accrual |
| NCT04441099 | NBE-002 in Patients With Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Jun 22, 2020 | NBE-Therapeutics AG | End of Program | Other (stated, no rule matched) |
| NCT02585388 | Addition of Aromatase at the Navelbine in Pretreated Metastatic Breast Cancer.(CHEOPS) | Phase 2 | terminated | Oct 23, 2015 | ARCAGY/ GINECO GROUP | Treatment toxicity | Safety / toxicity |
| NCT01975597 | Pilot Study of Bone Biopsy and Aspirate in Women With Metastatic Breast Cancer | — | terminated | Nov 4, 2013 | University of Michigan Rogel Cancer Center | held for blocking amendment then determined not to re-open | Other (stated, no rule matched) |
| NCT04720664 | Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer(OASIS) | Phase 2 | terminated | Jan 22, 2021 | Georgetown University | Lack of efficacy | Efficacy / futility |
| NCT04385433 | A Comparative Study of Pravastatin vs Placebo as Primary Prevention of Severe…(PRAVAPREV-01) | Phase 3 | terminated | May 13, 2020 | Institut du Cancer de Montpellier - Val d'Aurelle | Not enough patients enrolled | Enrollment / accrual |
| NCT03329378 | Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer | Phase 2 | terminated | Nov 6, 2017 | Icahn School of Medicine at Mount Sinai | Data Safety Monitoring Board is in agreement with the study findings so far and the stopping rule… | Safety / toxicity |
| NCT04092816 | Fathers and Mothers Invested in Lives of Their Youth (FAMILY) Study: A Pilot Intervention(FAMILY) | N/A | terminated | Sep 17, 2019 | UNC Lineberger Comprehensive Cancer Center | The study was stopped prematurely due to difficulty meeting accrual and retention goals,… | COVID-19 / pandemic |
| NCT04185311 | Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating… | Phase 1 | terminated | Dec 4, 2019 | Jonsson Comprehensive Cancer Center | enrollment | Enrollment / accrual |
| NCT05365243 | A Pilot Study to Evaluate the Use of the AMMA Portable Scalp Cooling System From Cooler… | N/A | withdrawn | May 9, 2022 | Cooler Heads Care Inc. | Single-site study, site was unable to participate | Other (stated, no rule matched) |
| NCT00455039 | INST 0514C- Biologic Correlative Study: Trial of GW572016 in HER2 Overexpressing Breast… | Phase 1 / Phase 2 | withdrawn | Apr 3, 2007 | University of New Mexico | This is a duplicate record and the sponsor has submitted under NCT00206427. | Other (stated, no rule matched) |
| NCT01712815 | PET/CT in Evaluating Response to Chemotherapy in Patients With Breast Cancer | N/A | terminated | Oct 24, 2012 | University of Southern California | Insufficient accrual | Enrollment / accrual |
| NCT00765765 | Ixabepilone and Hydroxychloroquine in Treating Patients With Metastatic Breast Cancer | Phase 1 / Phase 2 | terminated | Oct 3, 2008 | University of Medicine and Dentistry of New Jersey | Slow accrual | Enrollment / accrual |
| NCT04639245 | Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous… | Phase 1 / Phase 2 | terminated | Nov 20, 2020 | Fred Hutchinson Cancer Center | Terminated due to slow accrual. | Enrollment / accrual |
| NCT03576131 | GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors | Phase 1 / Phase 2 | terminated | Jul 3, 2018 | Genmab | Sponsor decision | Sponsor / business decision |
| NCT04901299 | Fulvestrant + Neratinib In Breast Cancer(HER2-Signal) | Phase 2 | withdrawn | May 25, 2021 | Massachusetts General Hospital | Team decision | Other (stated, no rule matched) |
| NCT04936451 | Electrotherapy in the Management of Myofascial Syndrome(MODYMYO) | N/A | terminated | Jun 23, 2021 | Institut Cancerologie de l'Ouest | lack of recrutment | Other (stated, no rule matched) |
| NCT04424641 | A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid… | Phase 1 / Phase 2 | terminated | Jun 11, 2020 | Genmab | Study was terminated due to MTD was reached | Other (stated, no rule matched) |
| NCT05809895 | Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With…(AdvanTIG-211) | Phase 2 | withdrawn | Apr 12, 2023 | Novartis Pharmaceuticals | Business decision, not driven by safety concerns; no new safety signals have been observed in the… | Safety / toxicity |
| NCT05428709 | Women In Steady Exercise Research - Window of Opportunity for Exercise and Tumor Biology(WISER-WIN) | N/A | terminated | Jun 23, 2022 | Milton S. Hershey Medical Center | PI leaving academia | Other (stated, no rule matched) |
| NCT04541225 | Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid… | Phase 1 | terminated | Sep 9, 2020 | Nuvation Bio Inc. | Sponsor decision | Sponsor / business decision |
| NCT05191004 | Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC | Phase 1 / Phase 2 | withdrawn | Jan 13, 2022 | Nuvation Bio Inc. | Sponsor decision | Sponsor / business decision |
| NCT05255666 | Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer… | Phase 2 | withdrawn | Feb 24, 2022 | Washington University School of Medicine | No drug | Other (stated, no rule matched) |
| NCT02067741 | CR1447 in Endocrine Responsive-HER2neg and TN-ARpos Breast Cancer | Phase 2 | terminated | Feb 20, 2014 | Swiss Cancer Institute | The SAKK board decided to prematurely end the life-long follow-up of the trial SAKK 21/12, as 90%… | Other (stated, no rule matched) |
| NCT00002668 | Pain Control in Patients With Recurrent or Metastatic Breast or Prostate Cancer | N/A | terminated | Jan 27, 2003 | Eastern Cooperative Oncology Group | Slow accrual | Enrollment / accrual |
| NCT00002934 | Evaluation of Breast Cancer Recurrence Rates Following Surgery in Women With Ductal… | Phase 2 | terminated | Apr 16, 2003 | Eastern Cooperative Oncology Group | This study was terminated when the accrual goal for the low/intermediate grade stratum was reached.… | Enrollment / accrual |
| NCT03060356 | Autologous T Cells Expressing MET scFv CAR (RNA CART-cMET) | Early Phase 1 | terminated | Feb 23, 2017 | University of Pennsylvania | Halt in funding | Funding |
| NCT04896320 | Tucatinib With Chemotherapy and Trastuzumab in Advanced Her-2-neu Overexpressing,…(2019-101826) | Phase 1 / Phase 2 | withdrawn | May 21, 2021 | Providence Health & Services | Study will be closed due to zero enrollment. | Enrollment / accrual |
| NCT05431582 | Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and… | Phase 1 | withdrawn | Jun 24, 2022 | M.D. Anderson Cancer Center | No participants enrolled | Enrollment / accrual |
| NCT04348916 | Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With… | Phase 1 | terminated | Apr 16, 2020 | Oncorus, Inc. | Terminated due to Oncorus portfolio reprioritization | Sponsor / business decision |
| NCT04675450 | NBP in Women With Metastatic Breast Cancer to Prevent Nab-paclitaxel Induced Toxic… | Phase 2 | withdrawn | Dec 19, 2020 | Conjupro Biotherapeutics, Inc. | Further preclinical development activities required to proceed | Other (stated, no rule matched) |
| NCT03152929 | Paravertebral Block (PVC) Versus Pectoral Nerve Block (PEC) | Phase 3 | terminated | May 15, 2017 | Corewell Health West | Standards of care changed at the institution so that PEC procedures were no longer common or… | Other (stated, no rule matched) |
| NCT04305236 | Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast… | Phase 2 | terminated | Mar 12, 2020 | University of California, Irvine | Halted due to study funding | Funding |
| NCT00074269 | Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for… | Phase 2 | terminated | Dec 11, 2003 | University of California, San Diego | Terminated early due to poor enrollment | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 24 days agoSource updated Oct 16, 2023source: clinicaltrials